2019 Future Healthcare 100 List Opens for Submissions: Over 130 Listed Companies Across Three Editions Secure Follow-on Funding

All great feats in the world are accomplished in silence. Whether it is groundbreaking innovation in an era of transformation or the steadfast adherence to an extraordinary inner conviction amidst the ordinary, all stem from a remarkable aspiration. Embarking on a journey into the unknown and treading a rugged path, we firmly believe that each step is not an endpoint, but an opportunity for transcendence.

Such a group serves as the pebbles that stir ripples of change in the pond. In the realm of healthcare innovation, they are Chinese innovative enterprises that truly represent the future of medicine. Building upon technological upgrades, they achieve leaps in service delivery; against the backdrop of shifting public perceptions, they subtly transform our lives, exploring deconstructible patterns for medical transformation.

The VB100 List, established by VCBeat and Eggshell Research Institute, is China’s first ranking focused on innovative healthcare companies that are not publicly listed. It aims to select Chinese innovative healthcare enterprises that truly represent the future of medicine, identify the core forces driving China’s future healthcare industry, and promote innovation and transformation in the health and medical sector.

In 2019, the call for nominations for the Future Healthcare Top 100 List was launched.RankingsPrimary CoverageHealthcare Services, Innovative Biopharmaceuticals, Medical Devices, Digital Health, and Overseas Healthcare;andAnnual Investment Hotspots，including but not limited to immunological techniques, microbiology, gene editing, the Internet of Things (IoT), and cloud computing servicesField, ranking based on core dimensions such as institutional investor valuations, cumulative funding amounts, corporate growth rates, creditworthiness, and reputation.

Since the inception of the ranking,The “Top 100 Future Healthcare Companies” list has become a bellwether for investment in the medical and health sector, guiding development and investment trends in China’s healthcare innovation landscape both currently and in the foreseeable future., providing reference and guidance for the subsequent financing of innovative enterprises.

Among the companies that have appeared on the list in previous years, the pharmaceutical e-commerce platform 111.com (Yiyaowang) was listed consecutively in 2016 and 2017, secured RMB 50 million in strategic financing from Allcare & Yucheng Capital in 2018, and completed its IPO in September of the same year. Similarly, Ping An Good Doctor, a comprehensive healthcare platform that also made the list for two consecutive years in 2016 and 2017, achieved rapid growth within the Ping An ecosystem and completed its IPO in just three years. The maternal and child health platform Babytree went public in 2018. SoYoung, a medical aesthetics platform operating in the consumer healthcare sector like Babytree, was listed for two consecutive years starting in 2016 and completed its IPO this May. Furthermore, Berry Genomics and BGI Health, which ranked among the top in the 2016 Future Healthcare 100 list, also went public one after another the following year.

Furthermore, according to incomplete statistics, more than 130 listed companies have successively secured new rounds of financing after the release of the ranking, with their financing stages advancing accordingly. The number of companies at Series A is decreasing, while those at Series C are increasing. Among the 100 companies on the 2018 list, over 50 obtained new financing in 2018, reflecting an overall advancement in financing stages. WeDoctor, which has been on the list for three consecutive years, has progressed from Series C to pre-IPO, accompanied by a substantial increase in its valuation.

Since 2016,More than 1,000 high-potential innovative enterprises made the list, with over 400 innovative enterprises added in 2018 alone.The annual "Top 100 Future Healthcare Companies" list serves not only as a reaffirmation of the industry’s development trends for the current year, but also as a forecast for the trajectory of the medical and health sector in the coming year.

2016 marked the inaugural year of internet healthcare, as well as the gradual launch of the Future Healthcare 100 list.Total valuation reachesAmong the listed companies with a combined valuation of RMB 248.4 billion, 14 are internet-based integrated healthcare platforms, and 8 are innovative enterprises dedicated to healthcare informatization. Internet healthcare companies account for the highest proportion and hold the largest market capitalization on the list, with service-driven enterprises centered on online medical consultation services occupying the core positions.

By 2017, Berry Genomics and BGI had gone public in succession, while more than 30 Chinese biotech companies focused on genetics secured new rounds of financing. Genetics became the central theme of innovation and development in the healthcare sector that year, with 19 innovative genetic companies making the list, boasting a combined valuation of RMB 47.33 billion, accounting for 14.8% of the total valuation of all listed enterprises. Meanwhile, after a year of explosive growth, comprehensive healthcare platforms shifted their focus toward core medical services and expanded into offline operations. Ten such platforms broke through the single-model constraint of online consultations and stood out, earning a place on the 2017 Top 100 List.

In 2018,Driven by capital, the healthcare market is developing healthily overall, with unicorn companies continuing to grow. The total valuation of listed companies exceedsRMB 420 billion, a substantial 32.2% increase from 2017. The combined valuation of the top 10 companies exceeded RMB 200 billion, approaching the total valuation of the top 100 companies in 2016. Technology has gradually become a breakthrough point in the healthcare sector, with 23 innovation-driven companies led by artificial intelligence and big data making the list, among which gene sequencing has begun to stand out. In addition, comprehensive medical platforms and healthcare informatization remain sectors with a significant number of listed companies.

According to statistics from VCBeat, the fields of medical devices, pharmaceuticals, and biotechnology were the most “crowded” in 2019, representing what can be described as the “rigid demand” of the entire healthcare industry. After penetrating the consumer sector, the internet has gradually entered the healthcare field, attempting to address various pain points of traditional medical services through innovations in processes and business models. Furthermore, national planning proposes the establishment of a new system for biopharmaceuticals, with the bioindustry designated as a strategic emerging industry by the state.

We have analyzed current healthcare development trends and integrated them with prevailing investment trends to further upgrade the 2019 Future Healthcare Top 100 List, establishing5 Main Charts, Series Sub-Charts, and 12 Specially Added Pengcheng Awards Covering the Entire Field of Healthcare Innovation. The main rankings are divided into five categories: China Healthcare Services Ranking, China Innovative Pharmaceuticals Ranking, China Innovative Medical Devices Ranking, China Digital Health Ranking, and Overseas Healthcare Innovation Ranking.

The sub-ranking primarily targets companies in investment hotspots of 2019 with significant potential for subsequent financing. The Pengcheng Award mainly evaluates investment institutions, innovative enterprises, hospitals, and industry figures. It aims to depict the profound transformation of the healthcare industry, gain insights into the patterns of industrial evolution, and promote the positive and rapid development of the health and medical sector, with a focus on benchmark enterprises and individuals driving innovation and change.

The 2019 Future Healthcare 100 Conference, centered on the Future Healthcare 100 Ranking, isA premier event bridging healthcare and capital, bringing together 10,000 attendees, 1,000 innovative enterprises, and 500 investment institutions。VCBeat will join forces with innovative enterprises listed in the “Top 100 Future Healthcare Companies” to create China’s first collective voice and top-tier capital matchmaking platform for companies featured on the “Top 100 Healthcare Valuations” list.

Media Exposure:The list will be released at the 2019 Top 100 Future Healthcare Companies Conference, and award-winning enterprises and individuals will receive their medals and trophies at the event.

In-Depth Dialogue:Top-Ranked Companies Have the Opportunity to Be Invited to the 2019 Future Healthcare 100 ConferenceDeliver a live on-site presentation and engage in dialogue with numerous industry leaders, capital investors, and academic experts.

Subsequent Developments:High-quality listed companies will have the opportunity to engage in in-depth follow-up collaborations with VCBeat, gaining access to a series of featured reports and investment and financing matchmaking opportunities.。

Submission Period: September 16–November 15

Application Method: Registration via the official website,https://vcbeat.top/Theme/VB2019List